Hepatitis A

Lore & Background

Hepatitis A is caused by a picornavirus of the genus Hepatovirus, with humans and other vertebrates as natural hosts. The virus is non-enveloped, contains positive-sense single-strand RNA, and has one serotype but multiple genotypes. It is resistant to detergents, acid, solvents, drying, and temperatures up to 60 °C, and can survive months in fresh and salt water. The virus primarily replicates in hepatocytes and Kupffer cells, and is excreted in bile and stool. No chronic infection has been reported.

Reader's Guide

Hepatitis A is a significant global cause of acute viral hepatitis, with around 1.4 million symptomatic cases and 114 million total infections annually. It is more common in areas with poor sanitation and unsafe water; in developing regions, about 90% of children are infected by age 10, conferring lifelong immunity. Outbreaks often occur in moderately developed countries where childhood exposure is low and vaccination is not widespread. The hepatitis A vaccine is effective for life, and preventive measures include hand washing and proper cooking. No specific treatment exists, but infections usually resolve completely; acute liver failure, though rare, may require transplantation. World Hepatitis Day on July 28 raises awareness of viral hepatitis.

Did You Know?

• Many cases, especially in children, have few or no symptoms.
• Around 10–15% of people experience a recurrence of symptoms within six months after the initial infection.
• The virus can survive for months in fresh and salt water.
• After a single infection, a person is immune for life.

Routes of Infection and Who Is at Risk

The hepatitis B virus travels through contact with infectious blood and body fluids, a fact that shaped its original nickname, "serum hepatitis." In regions where the disease runs rampant, the most common pathway is infection around the time of birth or through childhood encounters with another person's blood. Where the virus is uncommon, the picture shifts: intravenous drug use and sexual contact become the dominant routes. Healthcare workers, dialysis patients, recipients of blood transfusions, and people sharing households with an infected individual all face elevated risk, as do travelers to high-prevalence countries and those in group-living settings. During the 1980s, unsterilized tattooing and acupuncture equipment accounted for a notable share of new cases, though stricter sterilization practices have since reduced that threat. Importantly, the virus does not spread through casual contact—holding hands, sharing cutlery, kissing, hugging, coughing, sneezing, or breastfeeding all pose no risk. Hepatitis B is one of five principal hepatitis viruses (A through E), and its transmission profile distinguishes it sharply from respiratory or foodborne pathogens.

From Acute Illness to Chronic Disease

After exposure, the incubation period spans roughly thirty to one hundred eighty days before symptoms surface. When illness strikes, it often arrives as a rapid onset of nausea, vomiting, fatigue, abdominal pain, dark urine, and yellowing of the skin. For most people this acute phase eases within a few weeks, though some may feel unwell for up to six months. Deaths during the acute stage are rare, though a small number of patients develop fulminant hepatic failure. The six-month mark is the critical threshold: beyond it, the infection is classified as chronic. Age at the time of infection is the strongest predictor of that outcome. Approximately ninety percent of neonates who acquire the virus progress to chronic hepatitis B, while fewer than ten percent of those infected after age five do. Most chronic carriers remain completely asymptomatic, yet roughly a quarter will eventually develop cirrhosis or liver cancer. Diagnosis relies on blood tests that detect viral fragments and antibodies, typically performed thirty to sixty days after exposure. Chronic cases may be managed with antiviral drugs like tenofovir or interferon, though these medications are costly, and liver transplantation is sometimes necessary for advanced cirrhosis or hepatocellular carcinoma.

Vaccination and the Global Burden

Since 1982, a vaccine has served as the most powerful defense against hepatitis B, proving 98 to 100 percent effective. Full protection requires an initial dose plus two or three follow-up shots at later intervals. The World Health Organization recommends that infants receive their first dose within twenty-four hours of birth when possible, and by the end of 2021, national programs in 190 countries had integrated the vaccine into routine infant immunization. The WHO also advocates screening all donated blood before transfusion, administering antiviral prophylaxis to block mother-to-child transmission, and encouraging safe-sex practices including condom use. In 2016, the organization set a target to eliminate viral hepatitis as a global public-health threat by 2030, a goal requiring both prevention of new infections and therapeutic cures for chronic carriers. As of 2019, an estimated 296 million people—roughly 3.8 percent of the world's population—lived with chronic hepatitis B, while 1.5 million new acute infections arose that year. Eight hundred twenty thousand deaths were attributed to HBV, most from cirrhosis and liver cancer. Prevalence peaks in Africa at 7.5 percent and the Western Pacific at 5.9 percent, compared with 1.5 percent in Europe and 0.5 percent in the Americas.

Complications Beyond the Liver

While hepatitis B is primarily a liver disease, its reach extends well beyond the organ it targets. Chronic infection triggers a persistent inflammatory response in the liver that, over several years, can progress to cirrhosis and dramatically elevates the risk of hepatocellular carcinoma. Across Europe, hepatitis B and C together account for approximately half of all liver cancers. Patients with chronic HBV are strongly advised to avoid alcohol, which compounds the risk of both cirrhosis and malignancy. Beyond the liver, one to ten percent of infected individuals develop extrahepatic manifestations. These include a serum-sickness–like syndrome characterized by fever, skin rash, and polyarteritis, which often appears before jaundice sets in and may persist throughout the acute illness. Acute necrotizing vasculitis, known as polyarteritis nodosa, is another serious complication; roughly thirty to fifty percent of people with this condition are HBV carriers. Membranous glomerulonephritis, the most common form of HBV-associated kidney disease, is more frequently observed in children than adults. Papular acrodermatitis of childhood, also called Gianotti–Crosti syndrome, is another immune-mediated skin condition linked to the virus. Other hematological associations, including essential mixed cryoglobulinemia and aplastic anemia, have been documented, though their connection to HBV is less firmly established.

Gallery